Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898522 | 0.85 | FAAH (0.38) | — | |
| SCHEMBL25185960 | 0.85 | TRPV1 (0.34) | TSHRSQLE | |
| SCHEMBL6898520 | 0.85 | FAAH (0.38) | — | |
| SCHEMBL8769378 | 0.84 | — | — | |
| SCHEMBL25182435 | 0.83 | FAAH (0.41) | — | |
| SCHEMBL25178886 | 0.83 | FAAH (0.41) | — | |
| SCHEMBL25182585 | 0.83 | FAAH (0.41) | — | |
| SCHEMBL25185570 | 0.83 | FAAH (0.41) | — | |
| SCHEMBL19895436 | 0.83 | FAAH (0.46) | TSHR | |
| SCHEMBL261334 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865094-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4218935-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116271053-A | Treatment and diagnosis of melanoma | 洛克菲勒大学 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-3626309-B1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | UNIV ROCKEFELLER (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-110037999-B | Treatment and diagnosis of melanoma | 洛克菲勒大学（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
| US-10945978-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200230090-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3626309-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| US-5658942-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5604256-A | (7-(5-(1,3-DIOXANE-5YL)METHOXYIMINO-2-METHYL-8-(2-METHYLBUTYR -OXY)3-OXO-1,2,3,5,6,7,8,8A-OCTAHYDRO-1-NAPHTHYL)-3-HYDROXY-5 -OXOHEPTANOIC ACID AND SALTS | SANKYO COMPANY, LIMITED (JP) | 1997-02-18 | — | — | US | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0570245-B1 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO CO (JP) | 1996-10-30 | — | — | EP | disclosed |
| US-5403860-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0314435-B1 | OCTAHYDRONAPHTHALENE OXIME DERIVATIVES FOR CHOLESTEROL SYNTHESIS INHIBITION, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Sankyo Company Limited (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4997848-A | Enzyme inhibitors | SANKYO COMPANY, LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0314435-A2 | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition, processes for their preparation and compositions containing them | Sankyo Company Limited (JP) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945978-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | TSHR 2766/4885SQLE 4708/4885 |
| US-11865094-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | TSHR 2766/4885SQLE 4708/4885 |
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | TSHR 2766/4885SQLE 4708/4885 |
| US-20200230090-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | TSHR 2766/4885SQLE 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.